Responsivity of the Striatal Dopamine System to Methylphenidate-A Within-Subject I-123-β-CIT-SPECT Study in Male Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.
attention deficit/hyperactivity disorder (ADHD)
caudate nucleus
dopamine transporter (DAT)
methylphenidate
responsivity
single photon emission computed tomography (SPECT)
striatum
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
10
2021
accepted:
15
02
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning. Thirteen adolescent male patients (9-16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-β-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH. On-MPH status was associated with a highly significant change (-29.9%) of striatal DAT BP as compared to off-MPH ( Our findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity.
Sections du résumé
Background
UNASSIGNED
Methylphenidate (MPH) is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). MPH binds to the dopamine (DA) transporter (DAT), which has high density in the striatum. Assessments of the striatal dopamine transporter by single positron emission computed tomography (SPECT) in childhood and adolescent patients are rare but can provide insight on how the effects of MPH affect DAT availability. The aim of our within-subject study was to investigate the effect of MPH on DAT availability and how responsivity to MPH in DAT availability is linked to clinical symptoms and cognitive functioning.
Methods
UNASSIGNED
Thirteen adolescent male patients (9-16 years) with a diagnosis of ADHD according to the DSM-IV and long-term stimulant medication (for at least 6 months) with MPH were assessed twice within 7 days using SPECT after application of I-123-β-CIT to examine DAT binding potential (DAT BP). SPECT measures took place in an on- and off-MPH status balanced for order across participants. A virtual reality continuous performance test was performed at each time point. Further clinical symptoms were assessed for baseline off-MPH.
Results
UNASSIGNED
On-MPH status was associated with a highly significant change (-29.9%) of striatal DAT BP as compared to off-MPH (
Conclusion
UNASSIGNED
Our findings corroborate previous reports from mainly adult samples that MPH changes striatal DAT BP availability and suggest higher off-MPH DAT BP, likely reflecting low baseline DA levels, as a marker of symptom severity.
Identifiants
pubmed: 35492708
doi: 10.3389/fpsyt.2022.804730
pmc: PMC9046584
doi:
Types de publication
Journal Article
Langues
eng
Pagination
804730Informations de copyright
Copyright © 2022 Aster, Romanos, Walitza, Gerlach, Mühlberger, Rizzo, Andreatta, Hasenauer, Hartrampf, Nerlich, Reiners, Lorenz, Buck and Deserno.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neuroimage. 2008 Apr 15;40(3):1195-201
pubmed: 18282769
Rofo. 2006 Mar;178(3):272-7
pubmed: 16508833
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11047-54
pubmed: 11572967
J Comput Assist Tomogr. 1998 Mar-Apr;22(2):324-33
pubmed: 9530404
Psychol Rev. 2007 Oct;114(4):1047-75
pubmed: 17907872
Neuropediatrics. 2003 Apr;34(2):77-80
pubmed: 12776228
PLoS One. 2015 Sep 30;10(9):e0137326
pubmed: 26422146
PLoS One. 2013 May 15;8(5):e63023
pubmed: 23696790
Biol Psychiatry. 2007 Nov 1;62(9):1059-61
pubmed: 17511972
Nat Rev Neurosci. 2013 May;14(5):365-76
pubmed: 23571845
J Atten Disord. 2020 Jan;24(2):277-289
pubmed: 27178061
Trends Pharmacol Sci. 2013 Sep;34(9):489-96
pubmed: 23968642
Biol Psychiatry. 2007 Jun 15;61(12):1361-9
pubmed: 16950217
J Neurosci. 2012 Jan 18;32(3):841-9
pubmed: 22262882
Dev Med Child Neurol. 2001 Nov;43(11):755-60
pubmed: 11730150
Radiology. 1986 May;159(2):531-6
pubmed: 3485803
Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):306-11
pubmed: 12552351
Psychiatry Res. 2009 Aug 15;168(3):222-9
pubmed: 19545907
Acta Psychiatr Scand. 2012 Feb;125(2):147-56
pubmed: 22097933
Transl Psychiatry. 2021 Jan 25;11(1):74
pubmed: 33495438
EJNMMI Res. 2021 Aug 23;11(1):82
pubmed: 34424408
J Med Chem. 1991 Oct;34(10):3144-6
pubmed: 1920365
Dev Cogn Neurosci. 2016 Feb;17:57-67
pubmed: 26708774
Neuroimage. 2019 Jul 1;194:191-210
pubmed: 30677501
Lancet. 2020 Feb 8;395(10222):450-462
pubmed: 31982036
Pediatr Neurol. 2005 Sep;33(3):179-83
pubmed: 16139732
Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):352-9
pubmed: 17629732
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):443-50
pubmed: 19838702
Neuropsychology. 2015 Nov;29(6):874-81
pubmed: 25938917
Biol Psychiatry. 2011 Jun 15;69(12):e113-25
pubmed: 21531388
Mol Psychiatry. 2018 Sep;23(9):1929-1936
pubmed: 29230023
Biol Psychiatry. 2011 Jun 15;69(12):e145-57
pubmed: 21550021
Eur Arch Psychiatry Clin Neurosci. 2005 Dec;255(6):428-31
pubmed: 16091862
Psychiatry Res. 2013 Jul 30;213(1):24-30
pubmed: 23664625
J Atten Disord. 2013 Jul;17(5):374-83
pubmed: 23086616
Lancet Psychiatry. 2018 Sep;5(9):727-738
pubmed: 30097390
J Nucl Med. 1998 Sep;39(9):1500-8
pubmed: 9744331
J Am Acad Child Adolesc Psychiatry. 2017 Jul;56(7):602-609.e2
pubmed: 28647012
Eur J Nucl Med. 1990;17(3-4):127-9
pubmed: 2279492
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:294-300
pubmed: 29684537
Eur Neuropsychopharmacol. 2018 Oct;28(10):1059-1088
pubmed: 30195575
Am J Psychiatry. 2012 Oct;169(10):1038-55
pubmed: 22983386
Front Hum Neurosci. 2010 Feb 12;4:6
pubmed: 20179786
Science. 2020 Mar 20;367(6484):1362-1366
pubmed: 32193325
Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1119-27
pubmed: 15064872
Neuropsychopharmacology. 2007 Jul;32(7):1583-99
pubmed: 17164816
Ann Neurol. 1984 Mar;15(3):217-27
pubmed: 6609679
Neuropharmacology. 2004;47 Suppl 1:3-13
pubmed: 15464121
Psychiatry Res. 2000 Mar 6;93(2):165-78
pubmed: 10725533
Nat Rev Neurosci. 2016 Aug;17(8):524-32
pubmed: 27256556
Nat Rev Dis Primers. 2015 Aug 06;1:15020
pubmed: 27189265
Eur Child Adolesc Psychiatry. 2000 Dec;9(4):271-6
pubmed: 11202102
Clin Psychol Rev. 2005 Feb;25(2):183-213
pubmed: 15642646
Am J Psychiatry. 2012 Mar;169(3):264-72
pubmed: 22294258
Eur J Nucl Med. 2000 Oct;27(10):1518-24
pubmed: 11083541
J Atten Disord. 2011 Jan;15(1):36-45
pubmed: 20071637